| Neoadjuvant bleomycin, ifosfamide and cisplatin in cervical cancer. | |
| | |
MedLine Citation:
|
PMID: 1693316 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients with advanced and bulky early-stage cancer of the cervix have an unfavourable prognosis, which may be improved by initial neoadjuvant, cytoreductive chemotherapy. In a phase II study, coordinated at the West Midlands CRC Clinical Trials Unit, Birmingham, using ifosfamide (IFX) in combination with cisplatin and bleomycin (BIP) in advanced and recurrent cervical cancer, we demonstrated a response rate of 69%. This regimen produces rapid responses with acceptable toxicity and has potential for use as neoadjuvant therapy prior to radical radiotherapy in patients presenting with advanced and bulky early-stage disease. In an initial pilot study of this approach, 13 of 19 patients (68%) with primary inoperable disease showed significant tumour regression prior to radical local radiotherapy. Interim analysis of the first 66 patients entered into a randomized study evaluating the value of this approach has shown complete clinical tumour resolution after radical radiotherapy in 24/32 patients (75%) treated with up to three cycles of BIP prior to radiotherapy vs 19/34 patients (56%) treated with radiotherapy alone. There was no evidence that neoadjuvant chemotherapy enhances the acute toxic effects of pelvic radiotherapy. This approach has the potential for improving the outlook in patients with poor-prognosis primary disease. |
| | |
Authors:
|
J Tobias; E J Buxton; G Blackledge; J J Mould; J Monaghan; D Spooner; A Chetiyawardana |
Related Documents
:
|
14870766 - Management of metastatic spinal cord compression. 2615876 - Interstitial radiotherapy of malignant tumors of the vagina. 9209906 - Optimizing chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. 20409746 - Advances in radiotherapy for head and neck cancer. 10989896 - Recurrent nerve nodal involvement is associated with cervical nodal metastasis in thora... 15768476 - Lymphoma: present and future challenges. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: 26 Suppl ISSN: 0344-5704 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 1990 |
Date Detail:
|
Created Date: 1990-07-11 Completed Date: 1990-07-11 Revised Date: 2006-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: GERMANY, WEST |
Other Details:
|
Languages: eng Pagination: S59-62 Citation Subset: IM |
Affiliation:
|
West Midlands Cancer Research Campaign Clinical Trials Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Combined Chemotherapy Protocols / therapeutic use* Bleomycin / adverse effects, therapeutic use Cisplatin / adverse effects, therapeutic use Drug Evaluation Female Humans Ifosfamide / adverse effects, therapeutic use Middle Aged Random Allocation Uterine Cervical Neoplasms / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/BIP protocol; 11056-06-7/Bleomycin; 15663-27-1/Cisplatin; 3778-73-2/Ifosfamide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The potential for adjuvant therapy in early-stage cervical cancer.
Next Document: Palliative chemo-radiotherapy with ifosfamide and epirubicin as first-line treatment for high-risk m...